SCHEMBL2822774

SCHEMBL2822774

Cc1cc(NC(=O)Nc2ccc(-c3ccnc4c3c(N)nn4C)cc2)ccc1CN1CCN(C)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 12/20 0.66
CSF1R P07333 4/20 0.66
BLK P51451 4/20 0.66
KDR P35968 12/20 0.59
FLT3 P36888 6/20 0.59
SRC P12931 6/20 0.59
LCK P06239 3/20 0.59
LYN P07948 3/20 0.59
FLT4 P35916 3/20 0.59
ABL1 P00519 3/20 0.59
FLT1 P17948 2/20 0.59
FYN P06241 2/20 0.59
PDGFRA P16234 5/20 0.51
CDK1 P06493 1/20 0.46
CDK2 P24941 1/20 0.46
CDK8 P49336 1/20 0.46
TEK Q02763 1/20 0.46
FGFR4 P22455 1/20 0.45
MET P08581 1/20 0.44
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2817558 0.89 ABL1 (0.72) KITCSF1RBLKKDRFLT3
SCHEMBL2820492 0.86 KDR (0.66) KITCSF1RBLKKDRFLT3
SCHEMBL2820436 0.84 KDR (0.48) KITCSF1RBLKKDRFLT3
SCHEMBL1703245 0.82 KDR (0.78) KITCSF1RBLKKDRFLT3
SCHEMBL13041905 0.81 KIT (0.48) KITCSF1RBLKKDRFLT3
SCHEMBL1703132 0.80 CSF1R (1.00) KITCSF1RBLKKDRFLT3
SCHEMBL2816575 0.79 KDR (0.53) KITCSF1RKDRFLT3SRC
SCHEMBL1703567 0.79 KIT (0.83) KITCSF1RBLKKDRFLT3
SCHEMBL2821081 0.79 KIT (0.78) KITCSF1RBLKKDRFLT3
SCHEMBL1703118 0.78 KIT (0.74) KITCSF1RBLKKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061790-B1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them BAYER IP GMBH (DE) 2014-08-13 EP disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, FLT1 KIT 18/4885CSF1R 944/4885BLK 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.